Compare ARMOUR Residential REIT, Inc. (ARR) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Novavax Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.65 (market cap $2.07B), while Novavax Inc trades at $7.91 (market cap $1.31B). The key difference: ARMOUR Residential REIT, Inc. is the larger of the two by market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ARR | NVAX | |
|---|---|---|
Market Cap | $2.07B | $1.31B |
Sector | Financials | Health |
52-Week High | $19.12 | $11.19 |
52-Week Low | $14.05 | $6.22 |
Dividend Yield | 17.28% | — |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARR trades at $16.67, up 0.79% today, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a net income margin of 97.43% and a low P/E of 3.78, but revenue volatility and high investing cash outflows pose concerns. Recent dividends of $0.24 per share highlight income appeal, while analyst consensus is predominantly hold.
Outlook is cautious due to inconsistent EPS performance and significant cash flow swings, though valuation metrics suggest potential undervaluation. Risks include earnings misses and macroeconomic sensitivity, but the high dividend yield and low P/B ratio offer value for income-focused investors amid neutral market sentiment.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
